Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
99.163,17
0,49%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Contineum Therapeutics Inc (CTNM) Contineum Therapeutics Inc (CTNM) Notizie

Contineum Therapeutics Inc

CTNM
14,41
0,27 (1,91%)
24 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/12/202422:05BWContineum Therapeutics Initiates Patient Dosing in Phase 1b..
27/11/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/11/202414:05BWContineum Therapeutics to Attend the 7th Annual Evercore..
20/11/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202423:05EDGAR2Form 144 - Report of proposed sale of securities
18/11/202414:05BWContineum Therapeutics Expands Clinical Development of..
13/11/202422:05BWContineum Therapeutics to Attend Upcoming Investor..
06/11/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202422:08EDGAR2Form 8-K - Current report
06/11/202422:05BWContineum Therapeutics Reports Third Quarter 2024 Financial..
28/8/202422:05BWContineum Therapeutics to Present at Multiple Upcoming..
15/8/202400:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202418:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202418:19EDGAR2Form 8-K/A - Current report: [Amend]
13/8/202422:10EDGAR2Form 8-K - Current report
13/8/202422:05BWContineum Therapeutics Reports Second Quarter 2024 Financial..
31/7/202422:05BWContineum Therapeutics Announces Publication of Encouraging..
24/6/202422:05BWContineum Therapeutics Announces Appointment of Sarah Boyce..
04/6/202422:05BWContineum Therapeutics to Present at the 45th Annual Goldman..
03/6/202423:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202423:43EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/6/202422:05BWContineum Therapeutics Announces Appointment of John Healy..
31/5/202423:10EDGAR2Form 8-K - Current report
29/5/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202423:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202422:09EDGAR2Form 8-K - Current report
20/5/202422:05BWContineum Therapeutics Announces Appointment of Troy Ignelzi..
16/5/202423:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/5/202422:08EDGAR2Form 8-K - Current report
16/5/202422:05BWContineum Therapeutics Reports First Quarter 2024 Financial..
05/4/202403:02GLOBEContineum Therapeutics Announces Pricing of Initial Public..
Apertura: 14,15 Min: 14,08 Max: 14,566
Chiusura: 14,14

La tua Cronologia

NASDAQ
CTNM
Contineum Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network